Learn

With the prevalence of multiple sclerosis (MS) rising in Australia to affect over 33,000 people, the role of general practitioners is more vital than ever. As this is a progressive and often disabling condition, GPs are instrumental in recognising symptoms, facilitating referrals, and providing long-term care to help reduce the burden of the disease. 

With current best-practice guidelines now recommending the early use of high-efficacy disease-modifying therapies (DMTs) to improve long-term clinical outcomes, this educational activity is designed to enhance your knowledge of MS in this modern treatment era. This module provides a practical primer on modern DMTs and clarifies the GP's role in patient monitoring and treatment reviews. It will equip you to collaborate effectively with neurologists and confidently support your patients with MS.

Details

Disclaimer: Please note, once you click 'Register now' you will be leaving the AMA’s CPD Home website and entering a third-party education provider’s website. If you choose to register for this learning, you will need to provide some of your personal information directly to the third-party education provider. If you have any queries about how third-party education providers use, disclose or store your personal information you should consult their privacy policy.

Upon completion, your CPD activity record may take up to 4 weeks to be reflected on your CPD Home Dashboard.